VANCOUVER, BRITISH COLUMBIA--(Marketwire - February 28, 2008) - Chemokine Therapeutics Corp. (the “Company”) (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced the medical journal “Clinical & Experiment Metastasis” has published an article authored by Dr. Lee J Helman, Chief, Pediatric Oncology Branch, National Cancer Institute, regarding the Company’s lead anti-cancer drug CTCE-9908. The published article identifying that, in preclinical models of bone and skin cancer, treatment with CTCE-9908 reduced the number of gross metastatic lung nodules by 50% and markedly decreased micro-metastatic disease. The findings show that inhibition of the chemokine CXCR4/CXCL12 pathway decreases metastatic disease in two murine tumor models and expands on previous reports to describe the potential mechanism of action.
